Protocol Ledger

NCT06846398 · Phase II · ACTIVE NOT RECRUITING

A Phase 2 in Adult Subjects With Hereditary Angioedema

Interventional Phase II clinical trial protocol NCT06846398 sponsored by Shanghai Argo Biopharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-28 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06846398
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06846398
Protocol FieldVerified Registry Value
NCT IdentifierNCT06846398
Consolidated Lead SponsorShanghai Argo Biopharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2025-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI